Vanda Pharma FDA Panel Live Blog
 

Vanda Pharmaceuticals ( VNDA) brings its "sleeping pill for the blind" drug tasimelteon in front of an FDA advisory panel today.

Tasimelteon is a form of melatonin designed to regulate the 24-hour sleep-wake cycle, also known as circadian rhythm. For some people who are totally blind, having no light perception at all knocks the normal, 24-hour circadian rhythm off kilter. Their sleep patterns start to shift -- less sleep at night, more during the day.

The medical term for this condition is "non-24 sleep-wake disorder" (non-24) and there are no drugs approved to treat it.

Based on results from two phase III studies, Vanda believes tasimelteon is the first drug shown to "entrain" non-24 patients back into a normal circadian rhythm. Tasimelteon also improves sleep performance, the company says.

Experts participating in Thursday's FDA advisory panel will review the efficacy and safety data on tasimelteon and vote on whether or not the drug should be approved.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

Vanda Pharma (VNDA) Stock Price Target Upped on Drug Patent Ruling

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Strong On High Relative Volume: Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume

Vanda Pharmaceuticals (VNDA) Flagged As Strong On High Volume